6 completed, 2 not yet recruiting, 2 terminated, 2 withdrawn. 4 Not applicable, 3 Phase 3, 3 Phase 4, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 3, Not yet recruiting 1 |
| Phase 3 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 4 | 3 | Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Piracetam: new trials by email Literature Review of Piracetam trials Research Report on Piracetam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploring the Cognitive Benefits of a Blackcurrant-Based Supplement in Normobaric Hypoxia Nootropics (ginkgo biloba, nicergoline, piracetam, or others), Placebo - Cognitive Performance, Executive Function (Cognition) | Not applicable | Not yet recruiting | Leeds Beckett University | 27 | 2025-09-01 | 2025-09-10 |
| The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients Piracetam, Placebo - Diabetic Peripheral Neuropathy | Phase 4 | Not yet recruiting | Ain Shams University | 60 | 2025-02-10 | 2025-01-28 |
| Effect of a Plant Based Nootropic on Perceptual Decision Making. Nootropics (ginkgo biloba, nicergoline, piracetam, or others), Placebo, Perceptual decision-making performance - Cognitive Enhancement | Not applicable | Completed | University of Leeds | 37 | 2023-10-23 | 2024-11-14 |
| Subtherapeutic Dose of Piracetam as a Therapy Adherence Marker Piracetam - Drug Adherence Marker | Phase 4 | Unknown | The Netherlands Cancer Institute | 10 | 2023-07-03 | 2023-06-26 |
| Different Treatment Options Used for Post Covid-19 Syndrome Ginkgo biloba, Piracetam, Ginkgo biloba and Piracetam - COVID-19, Post COVID-19 Syndrome | Not applicable | Completed | Beni-Suef University | 90 | 2021-02-01 | 2026-07-28 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine Galantamine, Nootropics (ginkgo biloba, nicergoline, piracetam, or others) - Dementia, Alzheimer Disease | Completed | Janssen-Cilag G.m.b.H | 1134 | 2006-03-01 | 2014-06-18 | |
| Piracetam for Treatment Tardive Dyskinesia piracetam - Tardive Dyskinesia | Phase 3 | Completed | Beersheva Mental Health Center | 40 | 2003-08-01 | 2009-11-25 |
| Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI) Piracetam - Memory Disorders | Not applicable | Completed | UCB Pharma | 676 | 2000-05-01 | 2013-12-16 |
| A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke Piracetam, Placebo - Acute Ischaemic Middle Cerebral Artery Stroke | Phase 4 | Terminated | UCB S.A. - Pharma Sector | 571 | 1998-08-01 | 2013-08-30 |
| Piracetam for Treatment of Cocaine Addiction - 3 Piracetam - Cocaine-Related Disorders | Phase 1 | Completed | University of Pennsylvania | 1996-10-01 | 2015-10-06 | |
| A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome L-carnitine and piracetam, Placebo - Postpoliomyelitis Syndrome | Phase 3 | Withdrawn | Biolab Sanus Farmaceutica | 2015-11-17 | ||
| Piracetam for Treatment of Cocaine Addiction, Phase II - 4 Piracetam - Cocaine-Related Disorders | Phase 1 | Withdrawn | University of Pennsylvania | 2017-03-30 |
Cocaine-Related Disorders (2) · Dementia (2) · Alzheimer Disease (1) · Anxiety Disorders (1) · Aphasia (1) · Behavioral Symptoms (1) · COVID-19 (1) · Dementia, Vascular (1) · Depression (1) · Diabetes Mellitus (1) · Ischemia (1) · Medication Adherence (1) · Memory Disorders (1) · Neurobehavioral Manifestations (1) · Peripheral Nervous System Diseases (1)
University of Pennsylvania (2) · Ain Shams University (1) · Beersheva Mental Health Center (1) · Beni-Suef University (1) · Biolab Sanus Farmaceutica (1) · Hannover Medical School (1) · Janssen-Cilag G.m.b.H (1) · Leeds Beckett University (1) · The Netherlands Cancer Institute (1) · UCB Pharma (1) · UCB S.A. - Pharma Sector (1) · University of Leeds (1)
Germany (2) · United Kingdom (2) · United States (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Egypt (1) · France (1) · Greece (1) · Hungary (1) · Israel (1) · Italy (1) · Norway (1) · Poland (1)
Kyle Kampman, M.D. (2) · Acary Souza Bulle Oliveira, MD, PhD (1) · Alwin Huitema, Prof. Dr. (1) · Helge Frieling, Prof., MD (1) · Igor Libov, MD (1) · Ioannis Delis (1) · Vladimir Lerner, MD, PhD (1)
PMID 16306154, PMID 17685739, PMID 40149748
K20DA000238 (2)